## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($91.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Boston Scientific (BSX) Stock After Hours on Dec. 17, 2025: Analysts Stay Bullish as Shares Close Higher — What to Watch Before Thursday’s Open**
- Source: ts2.tech | 20251218T023012 | Bullish | Relevance: 100%
- Boston Scientific (BSX) shares closed higher on December 17, 2025, outperforming the broader market downturn, with analysts largely maintaining bullish ratings and price targets significantly above the current share price. The stock showed modest gains in after-hours trading, indicating investors positively received recent analyst updates. Investors are now looking to Thursday morning's macro data, specifically the November 2025 U.S. CPI release and weekly initial jobless claims, which could influence market sentiment and BSX's performance.

**2. Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?**
- Source: Finviz | 20251217T160745 | Neutral | Relevance: 100%
- This article evaluates Boston Scientific (BSX) based on Wall Street analyst recommendations and the Zacks Rank system. While BSX has a Strong Buy to Buy average brokerage recommendation, the article cautions against relying solely on these recommendations due to potential analyst bias. It suggests using the Zacks Rank, which is based on earnings estimate revisions and has a strong track record, as a more effective tool for investment decisions.

**3. Boston Scientific (BSX) Stock After Hours Dec. 18, 2025: Analyst Targets Shift, Options Point to Key Levels, and What to Watch Before Friday’s Open**
- Source: ts2.tech | 20251219T040756 | Somewhat-Bullish | Relevance: 100%
- Boston Scientific (BSX) closed Thursday, December 18, 2025, up 1.73% at $96.11, marking its third consecutive daily gain. Analyst sentiment for BSX remains bullish, despite Truist lowering its price target to $120 from $130, while UBS reiterated a $140 target. Investors are looking towards macro-economic releases on Friday morning and upcoming Q4 earnings as key drivers.

**4. August 2026 Options Now Available For Boston Scientific (BSX)**
- Source: Nasdaq | 20251218T170742 | Somewhat-Bullish | Relevance: 100%
- New August 2026 options are now available for Boston Scientific (BSX), offering opportunities for investors due to the time value before expiration. BNK Invest's YieldBoost formula highlights an $85.00 strike price put contract and a $100.00 strike price call contract for potential strategies like selling puts or covered calls, with associated return and risk analyses. Investors can use these new options for various strategies, including acquiring shares at a discount or boosting returns on existing holdings.

**5. Truist Financial Lowers Boston Scientific (NYSE:BSX) Price Target to $120.00**
- Source: MarketBeat | 20251218T151249 | Bullish | Relevance: 100%
- Truist Financial has decreased its price target for Boston Scientific (NYSE:BSX) from $130.00 to $120.00, while maintaining a "buy" rating, indicating a potential 24.09% upside. This adjustment comes despite Boston Scientific recently surpassing quarterly expectations and providing positive FY2025 guidance. The analyst consensus for BSX remains optimistic with a "Buy" rating and an average price target of $124.85.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Long-term trend broken: trading 5.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $141.7B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 27.5 |
| Current P/E | 31.5 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.1% to 2.1% (+3.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 47. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.08% (CS: 85) | Neutral |
| RSI_14 | 46.7 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 0.970x | Below |
| vs SMA200 | 0.947x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $95.58
- **Stop Loss:** $91.08 (4.7% risk)
- **Target:** $100.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 266
- **Position Value:** $25,424.28
- **Portfolio %:** 25.42%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*